Wuhan Hanyu Pharmaceutical

Hanyu Pharmaceutical (Wuhan) Biopharmaceutical Production Base covers a total area of 360 mu, with a planned total construction area of 250,000 square meters. It is mainly composed of four major parts: the "API Production Base", the "High-end Solid Formulation Production Base", the "Biologics R&D and Production Base" and the "Administrative and Living Service Center". Advanced technologies and equipment have been introduced to build a biopharmaceutical production base with a world-class level. The first phase plans to invest 2 billion RMB, with a total investment of 5 billion RMB. Hanyu Pharmaceutical (Wuhan) Co., Ltd. (abbreviated as: Wuhan Company) is a wholly-owned subsidiary of Shenzhen Hanyu Pharmaceutical Co., Ltd. (abbreviated as: Hanyu Pharmaceutical). The headquarters was approved by the State Securities Regulatory Commission in 2011 and listed on the ChiNext Board of the Shenzhen Stock Exchange (stock code: 300199). The registered capital is 100 million RMB, and it is mainly engaged in the research, development and production of active pharmaceutical ingredients and high-end formulations. The headquarters is located in Shenzhen High-tech Zone. It has built a national high-tech industrialization demonstration project peptide drug production base, a national peptide innovative drug public experiment center, a national peptide drug preparation pilot technology platform, and a peptide drug national-local joint engineering laboratory. Through modes such as introduction, digestion, and independent innovation, Hanyu Pharmaceutical has broken through the bottleneck of large-scale production technology for peptide drugs and formed more than 200 invention patents. It has successively undertaken more than 30 major scientific and technological research projects, including the National "863 Program", the National "Tenth Five-Year", "Eleventh Five-Year", and "Twelfth Five-Year" Science and Technology Major Projects, the Torch Program, and the National "Major New Drug Creation" program. It has participated in the formulation of 16 national peptide drug industry registration standards and the new edition of the "National Pharmacopoeia" standards. It has won provincial and municipal science and technology awards, patent awards, and quality awards for 6 consecutive years. Its main products are used in the treatment of digestive tract, cardiovascular and cerebrovascular, diabetes, infectious diseases, tumors, age-related diseases, etc. Hanyu Pharmaceutical has first-class laboratories for peptide drug synthesis, purification, lyophilization, quality research, formulation research, and pilot scale-up. It has introduced from the United States, Germany, Switzerland and other countries fully automatic peptide synthesis systems, rapid microwave peptide synthesis systems, large-capacity purification systems, laser desorption secondary mass spectrometry, electrospray mass spectrometry, large-capacity lyophilizers, ultra-high pressure liquid chromatography, gas chromatography, ion chromatography, and moisture analyzers and other special equipment. Among them, products such as desmopressin acetate injection, thymopentin for injection, somatostatin for injection, and terlipressin for injection have a leading domestic market share. Some APIs have been accepted by the US FDA and obtained DMF numbers. Many large distribution companies in the United States, Canada, Italy, India, Germany, Russia and other countries have become agents for Hanyu Pharmaceutical's series of products in the international market. Contact phone: ***********-5036 Contact email: whr@*